Skip to content
Screener

Absci Corporation ABSI Cash & Equivalents

Cash & Equivalents at other companies

Schrodinger logo
SchrodingerSDGR
$292.92M+26.3%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$556.82M+4.3%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$97.19M+100%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$145.07M+23.5%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$248.47M+152%
Assembly Biosciences logo
Assembly BiosciencesASMB
$31.12M+32.9%

Other financials

Income statement

See full
Revenue$215.0K-81.8%
Operating income-$30.8M-11.2%
Net income-$29.6M-12.3%
EPS (diluted)-$0.19+9.5%

Balance sheet

See full
Total debt$4.0M-37.2%
Total equity$172.0M-13.5%
Total assets$195.6M-15.9%

Cash flow

See full
Operating cash flow-$26.3M-20.5%
CapEx$30.0K+20.0%
Free cash flow-$26.3M-20.5%

Valuation

See full
Market cap$1.41B+235%
Enterprise value$1.4B+279%
P/S765.8×+664×

Profitability

See full
Operating margin-6,723%-14,525pp
Net margin-6,450.8%-13,699pp
FCF margin-5,365.2%-9,300pp

Returns & leverage

See full
Return on equity-63.9%+28.0pp
Debt / equity0.0×
Current ratio6.6×+0.9×

Where this comes from

Reported directly by Absci Corporation in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Absci Corporation’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:24 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001672688-26-000088
(In thousands)For the Three Months Ended March 31, 2026For the Three Months Ended March 31, 2025
Principal payments on long-term debt(460)(762)
Principal payments on finance lease obligations(47)
Proceeds from issuance of common stock, net7,95741,689
Proceeds from issuance of common stock through employee equity plans, net591,914
Net cash provided by financing activities7,55642,794
Net increase (decrease) in cash, cash equivalents, and restricted cash(11,389)5,911
Cash, cash equivalents and restricted cash - Beginning of period21,07858,214
Cash, cash equivalents, and restricted cash - End of period$9,689$64,125

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Absci Corporation's cash & equivalents?
Absci Corporation (ABSI) reported cash & equivalents of $9.69M in Q1 2026.
How has Absci Corporation's cash & equivalents changed year-over-year?
Absci Corporation's cash & equivalents decreased by 84.9% year-over-year, from $64.13M to $9.69M.
What is the long-term trend for Absci Corporation's cash & equivalents?
Over 5 years (2020 to 2025), Absci Corporation's cash & equivalents has grown at a -21.7% compound annual growth rate (CAGR), from $71.71M to $21.08M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Absci Corporation's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude